CAMBRIDGE, Massachusetts, April 2026
Iterative Health announced the successful close of a $77 million Series C funding round, reinforcing its mission to transform clinical research through AI-driven infrastructure and multispecialty site networks. The round was led by Intrepid Growth Partners and GV (Google Ventures), with participation from EDBI, Insight Partners, and Obvious Ventures, highlighting strong investor confidence in the company’s ability to address one of the most critical bottlenecks in drug development—slow and inefficient clinical trial execution. With nearly 90% of U.S.-based trials failing to meet enrollment timelines and many sites enrolling minimal patients, Iterative Health is positioning itself as a scalable solution to improve trial speed, patient access, and overall research efficiency.
AI-Powered Clinical Research Network Improves Trial Performance
Iterative Health has built a multispecialty clinical research network that integrates clinical trials directly into routine patient care, fundamentally redesigning how studies are conducted. Unlike traditional models, the company focuses on site performance and operational efficiency, combining centralized operations, expert staffing, and proprietary AI technology to optimize trial execution.
Its network spans over 100 research sites globally, across North America, Europe, India, and Australia, and collaborates with more than 40 pharmaceutical, biotech, and CRO partners. The results are clear: the platform delivers 2x faster site activation, reducing startup timelines by up to three months, and achieves 3x higher patient enrollment rates, significantly outperforming industry benchmarks. This directly addresses the biggest inefficiencies in clinical trials—delays in patient recruitment and site readiness.
Funding to Expand Therapeutic Areas and Global Reach
Advertisement
The newly secured capital will be used to expand Iterative Health’s footprint beyond gastroenterology and hepatology into high-growth areas such as cardiology and obesity, while also scaling its global site network and partnerships. The company is already collaborating with leading provider organizations, embedding research into healthcare delivery systems to ensure continuous patient access to clinical trials.
Additionally, the funding supports further development of its AI-driven platform, which enables faster decision-making, improved trial matching, and enhanced operational coordination across sites. This expansion strategy is designed to create a high-performance, globally connected research ecosystem capable of supporting large-scale, multi-therapeutic clinical studies.
Redefining Clinical Trial Execution with Scalable Infrastructure
Iterative Health’s approach reflects a broader industry shift toward digitally enabled, patient-centric clinical research models, where speed, scalability, and data-driven insights determine success. By embedding trials into everyday clinical workflows and leveraging AI to optimize execution, the company is helping sponsors and CROs reduce development timelines and accelerate access to new therapies. The addition of Ajay Agrawal to the Board of Directors and Anthony Philippakis as board observer further strengthens strategic oversight as the company scales.
This funding milestone underscores the growing importance of technology-enabled clinical research platforms in modern drug development. With strong financial backing, proven performance metrics, and an expanding global network, Iterative Health is positioning itself as a key enabler of faster, more efficient clinical trials, ultimately improving patient outcomes and accelerating innovation in healthcare.
Source: Iterative Health press release
